Cargando…

Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)

An important aim for improving TB treatment is to shorten the period of antibiotic therapy without increasing relapse rates or encouraging the development of antibiotic-resistant strains. In any M. tuberculosis population there is a proportion of bacteria that are drug-tolerant; this might be becaus...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeeves, Rose E., Marriott, Alice A. N., Pullan, Steven T., Hatch, Kim A., Allnutt, Jon C., Freire-Martin, Irene, Hendon-Dunn, Charlotte L., Watson, Robert, Witney, Adam A., Tyler, Richard H., Arnold, Catherine, Marsh, Philip D., McHugh, Timothy D., Bacon, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575197/
https://www.ncbi.nlm.nih.gov/pubmed/26382066
http://dx.doi.org/10.1371/journal.pone.0138253
_version_ 1782390749303668736
author Jeeves, Rose E.
Marriott, Alice A. N.
Pullan, Steven T.
Hatch, Kim A.
Allnutt, Jon C.
Freire-Martin, Irene
Hendon-Dunn, Charlotte L.
Watson, Robert
Witney, Adam A.
Tyler, Richard H.
Arnold, Catherine
Marsh, Philip D.
McHugh, Timothy D.
Bacon, Joanna
author_facet Jeeves, Rose E.
Marriott, Alice A. N.
Pullan, Steven T.
Hatch, Kim A.
Allnutt, Jon C.
Freire-Martin, Irene
Hendon-Dunn, Charlotte L.
Watson, Robert
Witney, Adam A.
Tyler, Richard H.
Arnold, Catherine
Marsh, Philip D.
McHugh, Timothy D.
Bacon, Joanna
author_sort Jeeves, Rose E.
collection PubMed
description An important aim for improving TB treatment is to shorten the period of antibiotic therapy without increasing relapse rates or encouraging the development of antibiotic-resistant strains. In any M. tuberculosis population there is a proportion of bacteria that are drug-tolerant; this might be because of pre-existing populations of slow growing/non replicating bacteria that are protected from antibiotic action due to the expression of a phenotype that limits drug activity. We addressed this question by observing populations of either slow growing (constant 69.3h mean generation time) or fast growing bacilli (constant 23.1h mean generation time) in their response to the effects of isoniazid exposure, using controlled and defined growth in chemostats. Phenotypic differences were detected between the populations at the two growth rates including expression of efflux mechanisms and the involvement of antisense RNA/small RNA in the regulation of a drug-tolerant phenotype, which has not been explored previously for M. tuberculosis. Genotypic analyses showed that slow growing bacilli develop resistance to isoniazid through mutations specifically in katG codon Ser(315) which are present in approximately 50–90% of all isoniazid-resistant clinical isolates. The fast growing bacilli persisted as a mixed population with katG mutations distributed throughout the gene. Mutations in katG codon Ser(315) appear to have a fitness cost in vitro and particularly in fast growing cultures. Our results suggest a requirement for functional katG-encoded catalase-peroxide in the slow growers but not the fast-growing bacteria, which may explain why katG codon Ser(315) mutations are favoured in the slow growing cultures.
format Online
Article
Text
id pubmed-4575197
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45751972015-09-25 Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315) Jeeves, Rose E. Marriott, Alice A. N. Pullan, Steven T. Hatch, Kim A. Allnutt, Jon C. Freire-Martin, Irene Hendon-Dunn, Charlotte L. Watson, Robert Witney, Adam A. Tyler, Richard H. Arnold, Catherine Marsh, Philip D. McHugh, Timothy D. Bacon, Joanna PLoS One Research Article An important aim for improving TB treatment is to shorten the period of antibiotic therapy without increasing relapse rates or encouraging the development of antibiotic-resistant strains. In any M. tuberculosis population there is a proportion of bacteria that are drug-tolerant; this might be because of pre-existing populations of slow growing/non replicating bacteria that are protected from antibiotic action due to the expression of a phenotype that limits drug activity. We addressed this question by observing populations of either slow growing (constant 69.3h mean generation time) or fast growing bacilli (constant 23.1h mean generation time) in their response to the effects of isoniazid exposure, using controlled and defined growth in chemostats. Phenotypic differences were detected between the populations at the two growth rates including expression of efflux mechanisms and the involvement of antisense RNA/small RNA in the regulation of a drug-tolerant phenotype, which has not been explored previously for M. tuberculosis. Genotypic analyses showed that slow growing bacilli develop resistance to isoniazid through mutations specifically in katG codon Ser(315) which are present in approximately 50–90% of all isoniazid-resistant clinical isolates. The fast growing bacilli persisted as a mixed population with katG mutations distributed throughout the gene. Mutations in katG codon Ser(315) appear to have a fitness cost in vitro and particularly in fast growing cultures. Our results suggest a requirement for functional katG-encoded catalase-peroxide in the slow growers but not the fast-growing bacteria, which may explain why katG codon Ser(315) mutations are favoured in the slow growing cultures. Public Library of Science 2015-09-18 /pmc/articles/PMC4575197/ /pubmed/26382066 http://dx.doi.org/10.1371/journal.pone.0138253 Text en © 2015 Jeeves et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jeeves, Rose E.
Marriott, Alice A. N.
Pullan, Steven T.
Hatch, Kim A.
Allnutt, Jon C.
Freire-Martin, Irene
Hendon-Dunn, Charlotte L.
Watson, Robert
Witney, Adam A.
Tyler, Richard H.
Arnold, Catherine
Marsh, Philip D.
McHugh, Timothy D.
Bacon, Joanna
Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title_full Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title_fullStr Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title_full_unstemmed Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title_short Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser(315)
title_sort mycobacterium tuberculosis is resistant to isoniazid at a slow growth rate by single nucleotide polymorphisms in katg codon ser(315)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575197/
https://www.ncbi.nlm.nih.gov/pubmed/26382066
http://dx.doi.org/10.1371/journal.pone.0138253
work_keys_str_mv AT jeevesrosee mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT marriottalicean mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT pullanstevent mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT hatchkima mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT allnuttjonc mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT freiremartinirene mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT hendondunncharlottel mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT watsonrobert mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT witneyadama mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT tylerrichardh mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT arnoldcatherine mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT marshphilipd mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT mchughtimothyd mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315
AT baconjoanna mycobacteriumtuberculosisisresistanttoisoniazidataslowgrowthratebysinglenucleotidepolymorphismsinkatgcodonser315